About Bortezomib Dosing
This guide provides supporting information for the Bortezomib Dose Calculator. Bortezomib is a proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. Its dosage is calculated based on Body Surface Area (BSA) to normalize the dose relative to patient size, which helps optimize therapeutic efficacy while managing potential toxicities.
Outputs Explained
The calculator provides three key outputs for clinical use:
- Body Surface Area (BSA): Calculated using the Du Bois formula from the patient’s height and weight. The calculator includes an option to cap the BSA at 2.0 m², a common practice to prevent potential overdosing in larger patients.
- Total Bortezomib Dose (mg): The final dose to be administered, calculated by multiplying the effective BSA (capped or uncapped) by the prescribed dose in mg/m².
- Volume to Administer (mL): The final volume for injection. This value depends on the administration route due to different standard reconstitution concentrations: 2.5 mg/mL for Subcutaneous (SC) and 1.0 mg/mL for Intravenous (IV) use.
How to Use the Calculator
- Enter Patient Metrics: Input the patient’s height and weight, ensuring the correct units (cm/in and kg/lbs) are selected from the dropdowns.
- Select Indication: Choose the treatment indication (e.g., Multiple Myeloma, Mantle Cell Lymphoma). This prefills the standard dose.
- Confirm Dose and Route: The standard dose (mg/m²) is editable for adjustments due to toxicity or specific protocols. Select the intended route of administration (SC or IV).
- Account for Hepatic Impairment: If applicable, select the severity of hepatic impairment based on total bilirubin levels. This will automatically adjust the recommended standard dose.
- Apply BSA Cap (Optional): Check the box to cap the BSA value at 2.0 m² for the final dose calculation.
- Review Results: The calculated Total Dose and Volume to Administer update automatically based on your inputs.
Dosing Overview
The standard starting dose for Bortezomib is typically 1.3 mg/m². The dosing schedule varies by indication and regimen but often involves twice-weekly administration for two weeks, followed by a rest period (e.g., on days 1, 4, 8, and 11 of a 21-day cycle).
Dose Adjustments:
- Hepatic Impairment: Dose reduction is required for moderate to severe hepatic impairment. The calculator automates this based on the selected severity.
- Renal Impairment: No dose adjustment is necessary for patients with renal impairment, including those on dialysis.
- Toxicity: Dose reductions or holds are necessary for significant toxicities, particularly peripheral neuropathy and thrombocytopenia, as outlined in the prescribing information.
Switching Administration Routes
Patients can be switched between intravenous (IV) and subcutaneous (SC) administration. The recommended dose (1.3 mg/m²) and total calculated dose (mg) remain the same regardless of the route.
The primary difference is the final concentration of the reconstituted solution, which affects the injection volume and may influence local site reactions. SC administration is often preferred as it has been associated with a significantly lower incidence of peripheral neuropathy compared to IV administration.
Missed Dose Protocol
If a dose of Bortezomib is missed, the dose should be administered as soon as possible, provided there is a minimum of 72 hours between the administered dose and the next scheduled dose. A patient should not receive two doses within a 72-hour period. The patient should be advised to contact their healthcare provider for specific instructions regarding their treatment schedule.
Safety Alerts
Adherence to safety protocols is critical when handling and administering Bortezomib.
- For Subcutaneous or Intravenous use ONLY. Administration by any other route (e.g., intrathecal) is FATAL.
- Key Adverse Reactions: Common and serious risks include peripheral neuropathy, hypotension, cardiac and pulmonary toxicities, gastrointestinal toxicity, thrombocytopenia, neutropenia, and tumor lysis syndrome.
- Antiviral Prophylaxis: Patients treated with Bortezomib are at an increased risk of Herpes Zoster reactivation. Antiviral prophylaxis (e.g., acyclovir) should be considered for all patients.
Frequently Asked Questions (FAQ)
Why is Body Surface Area (BSA) used for Bortezomib dosing?
BSA provides a more accurate measure of a patient’s metabolic mass than body weight alone, which is crucial for dosing cytotoxic agents to balance efficacy and toxicity.
What is the purpose of the “Cap BSA at 2.0 m²” option?
Capping BSA is a common clinical practice for certain chemotherapy drugs to avoid excessive doses and potential toxicity in patients with a very large BSA, though this practice should be guided by institutional protocols.
How does the calculator handle hepatic impairment?
It automatically reduces the standard dose (in mg/m²) based on the selected severity of impairment (Mild, Moderate, or Severe) according to prescribing guidelines.
Does the calculator adjust for peripheral neuropathy?
No. The tool provides reference tables on toxicity-based adjustments, but the clinician must manually enter the adjusted dose (e.g., 1.0 mg/m² or 0.7 mg/m²) into the “Standard Dose” field.
What is the difference between the SC and IV preparations?
The key difference is the reconstitution concentration. The SC route uses a more concentrated solution (2.5 mg/mL) than the IV route (1.0 mg/mL), resulting in a smaller injection volume.
Why is antiviral prophylaxis recommended?
Bortezomib treatment can reactivate the Varicella-zoster virus, leading to shingles. Prophylactic antiviral medication is recommended to prevent this complication.
Do I need to adjust the dose for a patient on dialysis?
No dose adjustment is required for renal impairment. Bortezomib can be administered after the dialysis procedure.
How long is the reconstituted solution stable?
When reconstituted with 0.9% Sodium Chloride, the solution is stable for up to 8 hours at room temperature in the original vial or a syringe.
References
This information is based on established clinical guidelines and prescribing information. For complete details, consult the official sources.
- VELCADE® (bortezomib) for injection, for intravenous or subcutaneous use. Prescribing Information. Takeda Pharmaceuticals America, Inc. View FDA Label
- European Medicines Agency (EMA). Velcade (bortezomib) Summary of Product Characteristics. View EMA SmPC
- Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487-2498. doi:10.1056/nejmoa043445
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. It is not a substitute for professional judgment. All clinical decisions, including dosing, must be made by a qualified healthcare professional based on the individual patient’s condition and the latest prescribing information.
